Santhera Pharmaceuticals

Big multibillion-dollar merger-and-acquisition deals have been few and far between in 2025, but that does not mean dealmaking has come to a standstill. In fact, based on Scrip ’s interviews and obser

Santhera Pharmaceuticals says that its Duchenne muscular dystrophy (DMD) treatment Agamree has got off to a strong start and while pricing negotiations are unsurprisingly proving tricky, the Swiss fi

The US Food and Drug Administration’s full approval of Sarepta Therapeutics, Inc. ’s Elevidys (delandistrogene moxeparvovec-rokl) pastes another jewel in the company’s “most contentious approvals” cr

In a recent discussion forum on China's WeChat social media platform, a group of patients whose sons are suffering from Duchenne muscular dystrophy (DMD) had good news to share - neurologists at one o